Envita's Aait - A Powerful Immunotherapy For Cancer

By Author: Henry Wronger
Total Articles: 6
Comment this article

AAIT is an acronym for autologous adoptive immune therapy and describes a therapy conceived from a patient’s blood, which is eventually re-infused during treatment. There are a plethora of strategies for Immunotherapy and just as many treatments that belong under the heading “autologous adoptive immunotherapy.” That said – not all options measure up to our standard..

Envita’s immunotherapy, AAIT, involves 4 major cell types including:

=> Natural killer cells

=> Natural killer T cells

=> Cytokine-induced killer cells

=> Cytotoxic T lymphocytes

The inclusion of Natural killer cells (NKs) and Natural killer T cells (NKTs) are the strategic focus of Envita’s AAIT immunotherapy serums.

Natural Killer Cells Important in Cancer Prognosis of Cancer

When NK cell numbers and functionality are low, cancer patients are predisposed to more aggressive tumor growth. And, as disease progresses, such declines are likely to continue. In both animal and human clinical trials, we have seen that ...
... by restoring NK and NKT function leads to enhanced cellular immune tumor-response and higher patient survival rates.

Keys to Envita's AAIT Uniqueness

1) Envita's protocol for AAIT is regulated to optimize the expansion of natural killer cells - the most potent cancer fighting component of the cellular immune system. Most immune therapies do necessarily use natural killer cells, however, those that do only expand them in sparse numbers with little activation.

2) Envita's AAIT protocol demands only 4-5 weeks to grow these cells, so patients can expect to experience benefits quickly. Moreover, while other immune therapies administer approximately 100-200 million cells per treatment, Envita delivers roughly 100 times as many during the course of treatment.

3) Myriads of published research studies demonstrate the effects of adoptive immune therapy in cancer patients by which Envita has identified and improved upon the most effective applications. Company protocol eschews the highest-level of Lyme disease procedure for the expansion and application of cells for each immunotherapy treatment.

4) In contrast to other published immune therapies, Envita's AAIT is the only one that can be administered as a “stand-alone.” Moreover, it may also be administered in conjunction with other therapies to enhance the cells’ effects in patients – a huge and incomparable benefit. Envita's AAIT therapy is not focused solely on expanding cells in the lab; rather, our intention is to keep them active until reintroduced into the patient’s body.

5) Envita’s AAIT guarantees far greater tumor kill, or cytotoxicity than that of other touted cancer cell vaccines / immunotherapy treatments found worldwide. Briefly, this means Envita’s activated natural killer cells in AAIT deliver shockingly higher tumor obliteration.

6) In conclusion, the most direct means with which to compare Envita’s proprietary immunotherapy against the others includes its:

a. Quality - based on cytoxicity (how much tumor the immune system can kill). Envita’s AAIT immunotherapy consistently delivers “significantly greater tumor eradication.

b. Quantity (how many cells you get back) – Envita’s AAIT immunotherapy delivers 100 times the cell dosage than all others.

c. Sterility (quality control measures) – Envita AAIT immunotherapy is guaranteed to be contaminant free.

If you have any inquiries with particular regard to Envita's AAIT immunotherapy, please consult Envita’s team of physicians and patient educators. This immunotherapy is utilized at Envita’s international cancer center in Mexico.

Lyme borreliosis is an infectious Lyme disease, arthritis as one of its symptoms can cause. The infection occurs when a tick which is infected with the spirochete bacteria Borrelia burgdorferi bites a human, and transmits the bacteria to the human.